文献速递消化系统肿瘤

吉西他滨/白蛋白结合型紫杉醇/S-1联合新辅助化疗用于动脉接触可切除胰腺癌的II期研究

A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact.
PubMed 文献 · Eur J Cancer · 2021-11-12

这项多中心单臂II期研究评估吉西他滨/白蛋白结合型紫杉醇/S-1(GAS)新辅助化疗在47例动脉接触临界可切除胰腺癌(BRPC-A)患者中的疗效与安全性,全部 eligible 患者完成6周期GAS,R0切除率86%,2年OS率70.1%、中位OS 41.0个月,III/IV级毒性发生率30%。

要点

  • 47例BRPC-A患者全部完成6周期GAS新辅助化疗,III/IV级毒性14例(30%)。
  • 45例(96%)接受潜在治愈性胰腺切除术,R0切除40例(86%)。
  • 2年OS率70.1%,中位OS 41.0个月,缓解率43%、疾病控制率96%。

核心结论

  • 作者认为,GAS新辅助化疗方案对BRPC-A显示出良好疗效且毒性较轻,带来高R0切除率和生存延长。

研究设计与样本

  • 多中心、单臂、II期研究,纳入47例动脉接触临界可切除胰腺癌(BRPC-A)患者。
  • 给药方案为第1天吉西他滨1000 mg/m2、第1天白蛋白结合型紫杉醇125 mg/m2、第1-7天S-1 60-100 mg/日,14天为一周期。
  • 完成6周期后评估可切除性与治疗反应,主要终点为2年总生存(OS)率和中位OS时间。

主要发现

  • 全部 eligible 患者完成6周期新辅助GAS方案。
  • 新辅助GAS期间III/IV级毒性发生于14例(30%)患者。
  • 缓解率为43%,疾病控制率为96%。
  • 45例(96%)接受潜在治愈性胰腺切除术,2例因疾病进展未手术。
  • 47例 eligible 患者中R0切除40例(86%);11例(24%)发生术后重大并发症(>III级),包括1例死亡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prognosis of patients with borderline resectable pancreatic cancer with arterial contact (BRPC-A) is extremely poor, and effective preoperative treatment is indispensable. We evaluated the clinical efficacy and safety of neoadjuvant chemotherapy, including gemcitabine, nab-paclitaxel and S-1 (GAS), for patients with BRPC-A. MATERIAL AND METHODS: A multicentre, single-arm, phase II study was performed. Patients were administered 1000 mg/m2 gemcitabine on day 1, 125 mg/m2 nab-paclitaxel on day 1 and 60-100 mg/day S-1 on days 1-7 during a 14-day cycle. Patients were then assessed for resectability and response to treatment after six cycles. The primary end-points were 2-year overall survival (OS) rate and median OS time (trial registration: jRCTs061180045, UMIN000016630). RESULTS: Forty-seven patients with BRPC-A were eligible for the present study. Six courses of neoadjuvant GAS regimen were completed in all eligible patients. The rate of grade III/IV toxicities occurred in 14 (30%) patients during the neoadjuvant GAS regimen. The response and disease control rates were 43% and 96%, respectively. Forty-five (96%) patients received potentially curative pancreatectomy, whereas two did not owing to disease progression. R0 resection was performed in 40 (86%) of 47 eligible patients. Eleven (24%) patients experienced postoperative major complications (>grade III), including one mortality. The 2-year OS rate and median OS time among 47 eligible patients were 70.1% and 41.0 months, respectively. CONCLUSIONS: The neoadjuvant GAS chemotherapy regimen for BRPC-A showed good efficacy with mild toxicity, resulting in a high R0 resection rate and prolonged survival in patients with BRPC-A.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Kondo N, Uemura K, Sudo T, et al. A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact. Eur J Cancer. 2021. PMID: 34781169. doi:10.1016/j.ejca.2021.10.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。